Save time and get answers to complex questions with AI chat
How to apply for vascepa's patient assistance?What are the most memorable drug brands in oral factor b inhibitors? in united statesWhat excipients are combined with ruxolitinib in apotex's medication?Novartis patent term dabrafenib?When will tenofovir alafenide come off patent in canada?
See the DrugPatentWatch profile for lipitor
I’m not able to pull the exact figure from the most recent filing at this moment, but here’s what the public quarterly reports tell us:
Pfizer’s earnings release for Q2 2023 notes that the decline in Lipitor sales is largely driven by the entry of generics in the U.S. and Canada. The company estimates that the generic competition has cut Lipitor’s revenue by roughly $200‑$250 million that quarter.
If you need the exact figure for a specific quarter, the most precise source will be the company’s Form 10‑Q or the earnings release on Pfizer’s Investor Relations site, where they break down the decline in detail.
Other Questions About Lipitor :